Genmab A (GMAB) Interest & Investment Income (2019 - 2026)

Genmab A has reported Interest & Investment Income for 6 years, with the latest figure at $44.0 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income fell 56.44% year-over-year to $44.0 million; the trailing twelve-month figure through Mar 2026 stood at $44.0 million (down 56.44% YoY), and the FY2025 full-year result was $408.0 million, up 163.26% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $44.0 million, down from $312.0 million in the prior quarter.
• The five-year high for Interest & Investment Income was $328.0 million in Q3 2024, with the low at -$645.0 million in Q4 2024.
• Historically, Interest & Investment Income has averaged -$58.7 million across 4 years, with a median of $44.0 million in 2026.
• Annual changes were most pronounced in 2024 — Interest & Investment Income plunged 115.72% — and 2025, when it advanced 10.92%.
• Genmab A's Interest & Investment Income stood at -$299.0 million in 2023, then plunged by 115.72% to -$645.0 million in 2024, then soared by 148.37% to $312.0 million in 2025, then plunged by 85.9% to $44.0 million in 2026.
• The last three Interest & Investment Income figures came in at $44.0 million (Q1 2026), $312.0 million (Q3 2025), and -$253.0 million (Q2 2025), per Business Quant data.